BPV

(redirected from bupivacaine)
Also found in: Dictionary, Medical, Wikipedia.
Related to bupivacaine: lidocaine
AcronymDefinition
BPVBlood Pressure Variability
BPVby-Pass Valve
BPVBusiness Purpose Vehicle
BPVBit Pointer Value
BPVBypass Valve (hydraulics)
BPVBenign Positional Vertigo
BPVBanca Popolare di Verona (Italian Bank)
BPVBack Pack Vacuum (various companies)
BPVBoiler and Pressure Vessel (American Society of Mechanical Engineers)
BPVBipolar Violation
BPVBullet Proof Vest
BPVBasis Point Value
BPVBreed Platform Verzekerden (Dutch: Broad Platform Insured)
BPVBovine Papilloma Virus
BPVBadminton Point Vienna (club; Vienna, Austria)
BPVBuilding Public Value (British Broadcasting Corporation; UK)
BPVBack Pressure Valve (oil and gas industry)
BPVBrake Proportioning Valve
BPVBupivacaine
BPVBullet Piercing Valve (ice maker installation)
BPVBusiness Process View
BPVBonnes Pratiques Vétérinaires (French: Good Veterinary Practices)
BPVBundesamt für Privat Versicherungen (Bern, Switzerland)
BPVBipropellant Valve
BPVBattle Planning and Visualization
BPVBackflow Prevention Valve
BPVBadminton du Pays Voironnais (French badminton club)
BPVBiologie et Pharmacologie du Vieillissement (French: Biology and Pharmacology of Aging)
BPVBleeding per Vagina
References in periodicals archive ?
In this in vitro model, bupivacaine, the most lipophilic LA, exhibited the greatest reduction in total and free drug concentration when treated with ILE compared to the other LAs.
HTX-011 provided superior and sustained pain reduction compared to placebo and bupivacaine solution through the critical 72-hour postoperative window, when pain is often most severe.
An experimental randomised controlled trial was conducted in 60 patients of ASA grade I & II undergoing laparoscopic cholecystectomy in King George hospital Visakhapatnam during January 2018-19 after obtaining permission from institutional ethical committee and written and informed consent from the patient with null hypothesis that intraperitoneal Hydrocortisone is as effective as Bupivacaine for pain relief.
The bupivacaine group had less pain at both 30 minutes (3.2 versus 5.7 points, P = .01) and 60 minutes (2.3 versus 5.9 points, P less than .001); 71% of women in the bupivacaine group had an average score of 4 or less, indicating adequate pain control, versus just 25% in the control arm (P = .003).
The rationale of study was to find out if administration of low dose bupivacaine is better in reducing the frequency of hypotension in spinal anesthesia during cesarean section.
HTX-011 is the first and only non-opioid, long acting local anesthetic to demonstrate in Phase 3 studies a statistically significant reduction in severe pain and an increase in the number of patients who require no opioids for 72 hours postoperatively versus bupivacaine solution, the standard-of-care.
According to the company, the overall safety profile of HTX-011, administered locally into the surgical site without a needle, is similar to that of the well-established safety profile of bupivacaine solution, without evidence of meloxicam-related toxicities.
Median dose of 0.5% bupivacaine in group B was 9(IQR=0.5)mg and minimum dose was 8mg.
The researchers found that the median pain score with movement at 48 hours postoperatively was 4 (in an 11-point scale) in the liposomal bupivacaine group and 3.5 in the placebo group (P = 0.72).
Results: After 5 minutes of spinal anesthesia, SBP significantly dropped in patients who received 0.75% hyperbaric bupivacaine as compared to patients who received 0.5% bupivacaine 107.95 +-13.49 mmHg vs.
21 patients in group 1 (levobupivacaine), 19 patients in group 2 (ropivacaine), and 22 patients in group 3 (bupivacaine) had a caudal effectiveness score of 3 (Figure 1).
The aim of the present study was to evaluate and compare the analgesic efficacy of ropivacaine (0.125%) and bupivacaine (0.125%) with fentanyl on mother, fetus, and on the course of labor.